Federated Hermes
RAPP

Federated Hermes’s Rapport Therapeutics RAPP Stock Holding History

Federated Hermes’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.47K Buy
143
+88
+160% +$2.48K ﹤0.01% 1902
2025
Q4 		$1.67K Buy
+55
New +$1.52K ﹤0.01% 1981

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Federated Hermes's RAPP Position: Q1 2026 in Review

Federated Hermes increased its Rapport Therapeutics (RAPP) stake by 160% in Q1 2026, buying an estimated $2.48K and bringing the position to 143 shares worth $4.47K. The position accounts for ﹤0.01% of the portfolio, ranked #1902.

Federated Hermes first reported a position in RAPP in Q4 2025 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Federated Hermes held 143 shares of Rapport Therapeutics worth $4.47K as of Q1 2026.
  • Federated Hermes bought 88 Rapport Therapeutics shares in Q1 2026, an estimated $2.48K.
  • Rapport Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1902 holding.
  • Federated Hermes first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.